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Beyond the positive traits, a side-effect of human-driven selective breeding is the inadvertently concentration of heritable muscle diseases among others, for which
mutations impact on electrical conduction, muscle contraction, and energy metabolism. Two of these genetic diseases, hyperkalemic periodic paralysis and malignant
hyperthermia, are reviewed in this project, which emphasizes the understanding of the molecular bases and pathophysiology, as well as aims to present the current state of
knowledge of the prevalence, clinical signs, diagnosis and treatment for each disease. 
A review of two equine channelopathies:
hyperkalemic periodic paralysis and malignant hyperthermia
Hyperkalemic periodic paralysis (HYPP) is a muscle disorder that affects
approximately 1.5% of the Quarter Horse and 4.5% of the Paint Horse breeds
descendants of the popular Quarter Horse stallion Impressive. Clinical signs consist
in episodes of myotonia and muscle fasciculations that can evolve to severe
weakness, recumbency and occasional death, usually coincident with elevated
serum potassium concentrations.
Tretament is principally focused on the reduction of hyperkalemia. An oncoming
episode of HYPP can sometimes be aborted with mild exercise or feeding grain. In
severe cases, administration of calcium gluconate (0.2– 0.4 ml/kg of a 23% solution
diluted in 2 L of 5% dextrose) will provide immediate improvement. Prevention of
HYPP attacks is based on regular exercise and dietary manage (<1.1% potassium
concentration) or administration of acetazolamide (2–4mg/kg q 12–14 h p.o.).
Malignant hyperthermia (MH) is a pharmacogenetic fatal disorder arised by the
disproportionate elevation of muscle activity induced by exposure to inhalation
anesthetics, succinylcholine or in some cases stress or excitement. Under
anesthesia, the clinical and laboratory findings are hyperthermia, tachycardia,
tachypnea, acidosis, muscle rigidity, rhabdomyolysis and electrolyte derangements.
Prevalence is estimated at 1.3% and mortalilty rate at 34%.
The HYPP mutation occurs in a highly conserved region of the  α subunit of the
skeletal muscle voltage-dependent sodium channel. The defective channel
presents a destabilisation of its inactivated state, resulting in decreased rates of
entry into and increased rates of exit from the inactivated state. Thus, an excessive
inward flux of sodium followed by an outward flux of potassium (hyperkalemia)
result in the fiber’s resting potential being close to the threshold potential and
hence more readily to elicit action potentials. 
Conclusions
In MH, the probabilities of RYR1 channel for the open state is increased and for the
close state is reduced. Halothane act directly to overcome the inhibition in
sensitized channels, resulting in an efflux of calcium from the sarcoplasmic reticulum
(SR) into cytosol and consequent activation of the contractile machinery. Soon, the
normal mechanisms of cytosolic calcium extrusion become overwhelmed:
Progress in understanding the genetic and molecular bases of equine muscle diseases such as hyperkalemic periodic paralysis and malignant hyperthermia, has enabled its fair
characterization and the development of DNA-based diagnostic tests to reduce or eliminate these genes from the populations. Currently, there are many inherited disorders
for which a genetic mutation is not yet known, so the research in this field still must grow to stop unknowing transmission of diseases to future generations and allow the
development of more targeted evidence-based treatments.
Family history, clinical signs, laboratory evaluation and electromyography have been
used in the diagnose of HYPP, however, definitive diagnosis can only be achieved









Early recognition of a MH reaction with immediate discontinuation of inhalated
anesthesia is decisive. While under anesthesia, the diagnose is based on classic
clinical signs. There is a rapid DNA test available to determine whether the
individual carries the mutation that confer susceptibility to MH.
Diagnosis
Therapy
If a horse is suspected with MH susceptibility, pretreatment with oral dantrolene
(4mg/kg) 30 to 60 min prior to anesthesia is recommended. Dantrolene inhibits the
calcium efflux from RYR1 receptors. However, caution must be taken, specially in
horses with hyperkalemic periodic paralysis, as dantrolene administration induces
hyperkalemia and adverse cardiovascular effects.
These processes consume large amounts of ATP, the main cellular energy carrier,
and generates excessive heat (hyperthermia). The muscle cell is damaged by the
depletion of ATP and cellular constituents leak into the circulation, including
potassium, myoglobin, creatine, phosphate and creatine kinase.
At the beginning of an attack, the inward current causes mild depolarization
leading to myotonia and muscle fasciculations. As the attack progresses more and
more muscle fibers become paralyzed as the more profound depolarization of the
muscle membrane causes inactivation of both mutant and wildtype channels, thus
rendering the muscle fiber inexcitable.
